ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2014
Anti-epileptogenic clinical trial designs in epilepsy: issues and options.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Thermosensitive, mucoadhesive brivaracetam nasal gel: a promising strategy for targeted relief of epilepsy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Nano-healing: Exploring the Therapeutic Potentials of Nanomedicine for CNS Disorders.Current pharmaceutical design · 2025Review
- Enhancing glymphatic fluid transport by pan-adrenergic inhibition suppresses epileptogenesis in male mice.Nature communications · 2024Article
- Insights into epileptogenesis from post-traumatic epilepsy.Nature reviews. Neurology · 2024Review
- A six-month prospective, randomised, double-blinded, placebo-controlled, crossover, dietary trial design to investigate the potential of psychobiotics on seizure semiology and comorbidities in canine epilepsy: study protocol.BMC veterinary research · 2023Article
- Neuropathophysiological Mechanisms and Treatment Strategies for Post-traumatic Epilepsy.Frontiers in molecular neuroscience · 2021Review
- Pharmaco-genetic inhibition of pyramidal neurons retards hippocampal kindling-induced epileptogenesis.CNS neuroscience & therapeutics · 2020Article
- Brivaracetam in the treatment of epilepsy: a review of clinical trial data.Neuropsychiatric disease and treatment · 2019Article
- Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy.Annals of neurology · 2018Article
- Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Epilepsia · 2018Review
- A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy.Scientific reports · 2017Article
- Prevention of Epilepsy: Issues and Innovations.Current neurology and neuroscience reports · 2016Review
- Review
- The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Novel concepts in epileptogenesis and its prevention.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Article
- 2014 Epilepsy Benchmarks: Progress and Opportunities.Epilepsy currentsArticle
- Article
- Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.Epilepsy currentsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although trials with anti-seizure drugs have not shown anti-epileptogenic or disease-modifying activity in humans, new compounds are on the horizon that may require novel trial designs. We briefly discuss the unique challenges and the available options to identify innovative clinical trial designs that differentiate novel anti-epileptogenic and disease-modifying compounds, preferably early in phase II, from current anti-seizure drugs. The most important challenges of clinical testing of agents for epilepsy prevention include having sufficient preclinical evidence for a suitable agent to proceed with a human trial of an anti-epileptogenic drug, and to demonstrate the feasibility of doing such a trial. Major challenges in trial design to assess agents for disease modification include the choice of suitable study parameters, the identification of a high-risk study population, the type of control, the time and duration of treatment, and a feasible follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.